Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex.
Harmony Biosciences has scored an expanded use for its Wakix narcolepsy drug to include cataplexy – a symptom of the sleep disorder that can cause total body collapse.
The FDA has approved Jazz Pharmaceuticals’ sleep disorder drug Xywav, to treat daytime sleepiness in patients with narcolepsy, offering a regime with less sodium than standard therapy.
PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for relapsed small cell lung cancer (SCLC).
Spain's PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin in the US, which is being teed up for a launch in 2020.